The PSYCH Virtual Investor Summit: Europe & Asia
Will connect a qualified investor community in Europe and Asia with the leaders from the most innovative and exciting businesses operating in the global psychedelic industry.
BUSINESS AND INVESTMENT
European companies set to have major role within international psychedelics industry.
Algernon Pharmaceuticals announces DMT study with Hammersmith Medicines Research.
Awakn to run Phase III trial for ‘Ketamine-Assisted Psychotherapy for Alcohol Use Disorder’.
Optimi Health and Numinus Wellness announce psychedelic research partnership.
Core One Labs finalises deal to acquire Ketamine Infusion Centers of Texas.
MindMed stock rises by 937% in a year.
Awakn Life Sciences and Prof David Nutt announce opening of ketamine clinic in the UK.
Delic Holdings set to acquire Complex Biotech Discovery Ventures.
Nova Mentis receives approval to progress clinical study on psychedelics and autism.
NeonMind files four provisional patents on psilocybin preclinical data.
Mindcure completes strategic equity investment in ATMA.
Optimi Health raises US$20.7m in IPO.
Silo Wellness announces successful completion of reverse take-over deal.
Core One Labs announces launch of synthetic psilocybin production.
PsyBio begins trial of synthetic psilocybin production.
Minerco purchases equipment to produce 1m microdoses of psilocybin daily.
Red Light Holland receives approval to sell psilocybin products in Brazil.
Numinus and Syreon provide update on the progress of their psilocybin trial.
Psilera Bioscience obtains DEA approval to conduct psychedelics research.
NeonMind purchases synthetic psilocybin from Psygen Labs.
Minerco purchases equipment to produce 1m microdoses of psilocybin daily.
RESEARCHERS DISCUSS RESULTS OF MICRODOSING PSYCHEDELICS
Researchers from Imperial College London have carried out the largest placebo-controlled trial into psychedelics to date and found that small doses of LSD boost the psychology of users in a manner of ways.
PROGRESS IN THE CARIBBEAN PSYCHEDELICS INDUSTRY
Last year, the Caribbean nation of Saint Vincent and the Grenadines launched an initiative to permit and support psychedelic research and wellness.
Enjoy the discussion between Stephen Murphy and Minster Saboto Caesar, who discuss the roll-out of the initiative as well as the future of the industry across the region.
RESEARCH AND SCIENCE
Prof David Nutt provides overview of Amanita Muscaria and its benefits.
The Aion International Center for Psychedelic Psychiatry opens in Jamaica.
Increase in use of psychedelics drives demand for unlicensed psychedelic guides in Vancouver.
Psychedelic therapy should be extended to couples needing counselling.
REPORT HIGHLIGHTS POTENTIAL ECONOMIC IMPACT OF PSYCHEDELIC MEDICINES IN THE US
Psychedelic-assisted therapies are experiencing a resurgence in interest across clinical trials, scientific studies and commercial investment and the industry is progressing faster than many analysts predicted.
This growth has been helped by the execution of clinical trials across Europe and the US, where results have been published in medical journals and shared by mainstream media outlets waking up to the potential transformative impact psychedelics could have on the economies and healthcare systems of countries around the world.
REGULATION AND LEGISLATION
Campaign to decriminalise psychedelics in Hawaii fails following vote.
The non-profit psychedelics company Therapsil joins lobby group in Canada.
Missouri lawmaker aims to include psychedelics in existing ‘right to try’ law.